[ad_1]
Concorde Corodex Group (CCG), one of the leading providers of water purification, water and wastewater treatment and environmental services in the Middle East, announced a joint venture with PolyAnalytik, a leading Canadian bioanalytics company, to establish a contract research organization (CRO) aimed at strengthening Research and testing infrastructure in the Middle East.
On the sidelines of ArabLab 2022, CCG and PolyAnalytik announced the launch of their premier contract research organization, Corodex Life Sciences.
The expertise of both parties to this strategic agreement will support new growth areas and improve the outcomes of the first-of-its-kind laboratory in the Middle East and Africa to conduct advanced molecular tests and deliver revolutionary technologies.
The joint venture will leverage the resources, knowledge and experience of both parties to support the research and testing market in the region and will provide contracted research services for new water treatment models, lake management, pharmaceutical, biotechnology, medical device industries and fire protection technology.
Mohanned Awad, Chief Commercial Officer of Concorde-Corodex Group, said: “Through a licensed and patented approach specializing in advanced molecular research, the new organization will assist local industries in developing innovative and effective products in areas such as petrochemicals, therapeutics, vaccines, food and agriculture. Biosciences and The cost and time for a medical device is a fraction of the international FDA approval.”
Amer Ebied, President of PolyAnalytik, said: “Through the joint venture, we will not only fill the local gap, but will also support companies in the UAE and the rest of the region to compete on the world stage, delivering the highest quality and most effective products. As we provide products from the idea stage From preclinical animal safety studies to comprehensive solutions at the regulatory clearance stage, we aim to be the clinical partner of choice for CROs on the successful journey of product development from early ideation to product launch.”
In addition to reducing the cost for companies to develop new drugs and medicines in niche markets, Cordex Life Sciences intends to simplify the drug market entry and development process. Along with government organisations, the newly formed joint venture also seeks to support foundations, research institutes and universities. –TradeArabia News Service
[ad_2]
Source link